- Wearable breast cancer screening tech advanced to final clinical trials.
- Company projects strong revenue growth, targeting Rs 825 crore for FY27
- Significant expansion of the dialysis network with 500 units by March 2027.
The shares of Lord's Mark Industries, which has a diversified presence across healthcare, including diagnostics, MedTech, dialysis, and advanced medical technologies, have been in action for the past week, rising nearly 15 per cent in a week--hitting upper circuits. The stock remained in focus on Wednesday, September 23, as well, rising 3.7 per cent to a high of Rs 99 on BSE as compared to last close of Rs 95.41.
Today's upward momentum in the stock was seen after the healthcare company announced that advancing in clinical trials for its cancer wearable device.
"Lord’s Mark Industries Limited, in collaboration with the Centre for Materials for Electronic Technology (C-MET), has advanced its AI-powered, radiation-free wearable breast cancer screening technology towards its final clinical trial stage, with trials planned across the USA, Great Britain and Europe," Lord's Mark Industries said in an exchange filing.
Last seen, the scrip was trading at Rs 97, up 1.67 per cent or Rs 1.59. Meanwhile, the company's market cap stood at over Rs 3,900 crore. The stock’s 52-week high was Rs 669.70 and a 52-week low was Rs 60.
Also Read: NSE IPO Allotment Finalised: Steps To Check Status On MUFG Intime India And BSE
Share Price History
The stock has been gaining momentum for the past five sessions, advancing over 15 per cent. According to BSE Analytics, Lords Mark Industries shares rose over 17 per cent in one month. In the last six months, it rose nearly 5 per cent. However, this year to date, the stock corrected over 85 per cent, and in a year it fell over 83 per cent.
What Could Be Top 3 Factors Behind Recent Rally In Healthcare Stock
1- Advancement in Clinical Trials: The company announced the advancement of its AI-powered, radiation-free wearable breast cancer screening technology (developed in collaboration with C-MET) to its final clinical trial stage across the USA, Great Britain, and Europe may have boosted investors' sentiment in today’s session.
2- Strong Revenue Projections: Earlier, in its September investor presentation, the company management projected revenues of approximately Rs 825 crore for the current fiscal year (FY27). This could be a reason behind the recent upward trend in the healthcare stock.
3- Dialysis Network Expansion: The company informed that the firm is actively expanding its dialysis network using AI-integrated technology, having secured orders exceeding 500 dialysis units to open 50 functional facilities by March 2027, alongside completing Phase 1 expansion at its Silvassa unit ahead of schedule.
Disclaimer: This story is for informational purposes only. It should not be construed as investment advice. Please seek expert advice before investing.